Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Improved Hematopoietic Stem Cell Mobilization for Gene Therapy of Hemoglobinopathies Using Single Agent Motixafortide | Synapse
March 3, 2026
Improved Hematopoietic Stem Cell Mobilization for Gene Therapy of Hemoglobinopathies Using Single Agent Motixafortide
SG
Stephan A. Grupp
Università Cattolica del Sacro Cuore
MG
Michael Grimley
Cincinnati Children's Hospital Medical Center
TD
Timothy Driscoll
See all
Key Points
Mobilization of hematopoietic stem cells improved significantly for gene therapy applications.
Key evidence includes a notable increase in mobilized stem cells and treatment efficacy.
This analysis focused on the effects of motixafortide on stem cell mobilization.
Enhanced mobilization can lead to better gene therapy outcomes for hemoglobinopathies.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Grupp et al. (Sun,) studied this question.
synapsesocial.com/papers/69a760cbc6e9836116a2ddef
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.036
Mark Helpful
Like
Save
Bookmark
Relay
Share